Dishman Carbogen Amcis' Q1 FY 2026-27 Quarterly Results

Result Summary

• Dishman Carbogen Amcis Ltd reported a 19.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 5.0%.
• Its expenses for the quarter were down by 9.2% QoQ and up 7.8% YoY.
• The net profit decreased 366.2% QoQ and decreased 347.2% YoY.
• The earnings per share (EPS) of Dishman Carbogen Amcis Ltd declined at 3.69 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Dishman Carbogen Amcis Ltd is a company that operates within the pharmaceutical industry, primarily focusing on providing contract research and manufacturing services (CRAMS) to the pharmaceutical and biopharmaceutical sectors. The company specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and offers a range of services from early-stage drug development to commercial manufacturing. As of the latest updates, there have been no significant developments reported for Dishman Carbogen Amcis Ltd. This overview provides a backdrop to understand its financial performance in the context of its operational focus within the pharmaceutical sector.

Revenue

The financial data for Dishman Carbogen Amcis Ltd indicates that the total income for Q1FY27 was ₹695.80 crores. This represents a decline of 19.8% on a quarter-over-quarter (QoQ) basis from Q4FY26, where the total income was ₹867.82 crores. Additionally, there was a year-over-year (YoY) decrease of 5.0% from Q1FY26, when the total income was ₹732.80 crores. These figures reflect the company's revenue performance within the given periods, showing a reduction in income both sequentially and compared to the same quarter of the previous fiscal year.

Profitability

In terms of profitability, the company reported a negative profit before tax of ₹-51.22 crores in Q1FY27, contrasting starkly with the positive ₹46.13 crores recorded in Q4FY26. This marks a significant decrease of 211.0% QoQ. Similarly, when compared to Q1FY26, where the profit before tax was ₹38.67 crores, there is a YoY decrease of 232.5%. The profit after tax for Q1FY27 was ₹-57.88 crores, a substantial drop from ₹21.74 crores in Q4FY26 and ₹23.41 crores in Q1FY26, reflecting decreases of 366.2% QoQ and 347.2% YoY, respectively. Earnings per share mirrored this trend, being ₹-3.69 in Q1FY27 compared to ₹1.39 in Q4FY26 and ₹1.49 in Q1FY26, exhibiting declines of 365.5% QoQ and 347.7% YoY.

Operating Metrics

The total expenses for Dishman Carbogen Amcis Ltd in Q1FY27 were ₹745.33 crores, showing a decrease of 9.2% from Q4FY26, where the total expenses were ₹820.54 crores. However, there was a YoY increase of 7.8% in expenses from Q1FY26, which recorded ₹691.48 crores. The tax expense for Q1FY27 was ₹6.66 crores, which is significantly lower than ₹24.39 crores in Q4FY26, marking a QoQ decrease of 72.7%. Compared to Q1FY26, where the tax was ₹15.26 crores, there was a YoY decrease of 56.4%. These metrics highlight the changes in the company's operational costs and taxation across the quarters.